William Blair Issues Optimistic Estimate for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Stock analysts at William Blair lifted their Q1 2025 earnings estimates for PTC Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn $10.04 per share for the quarter, up from their prior estimate of ($0.83). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.36) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at $6.47 EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.79) EPS.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analyst estimates of $437.16 million. The business’s revenue for the quarter was down 9.6% on a year-over-year basis. During the same period last year, the company earned ($1.20) EPS.

Several other research firms have also weighed in on PTCT. Robert W. Baird dropped their price objective on shares of PTC Therapeutics from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Wednesday. Morgan Stanley reiterated an “overweight” rating and issued a $70.00 price objective (up previously from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Bank of America upgraded PTC Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $55.00 to $68.00 in a report on Friday. Royal Bank of Canada upped their price target on shares of PTC Therapeutics from $57.00 to $58.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, StockNews.com upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and an average price target of $61.92.

PTC Therapeutics Price Performance

PTC Therapeutics stock opened at $44.23 on Friday. The business has a 50 day simple moving average of $48.86 and a 200 day simple moving average of $47.02. PTC Therapeutics has a one year low of $28.72 and a one year high of $58.38. The company has a market capitalization of $3.50 billion, a PE ratio of -7.45 and a beta of 0.52.

Insiders Place Their Bets

In other PTC Therapeutics news, CEO Matthew B. Klein sold 2,804 shares of the company’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $48.74, for a total value of $136,666.96. Following the completion of the sale, the chief executive officer now owns 273,234 shares of the company’s stock, valued at approximately $13,317,425.16. This represents a 1.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Lee Scott Golden sold 897 shares of PTC Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $46.95, for a total transaction of $42,114.15. Following the transaction, the executive vice president now directly owns 75,997 shares in the company, valued at approximately $3,568,059.15. This represents a 1.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,305 shares of company stock worth $1,682,755. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

A number of large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its holdings in shares of PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 270 shares in the last quarter. Sterling Capital Management LLC increased its stake in PTC Therapeutics by 424.4% during the 4th quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 522 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 320 shares during the period. GAMMA Investing LLC lifted its stake in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 441 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in shares of PTC Therapeutics in the fourth quarter valued at approximately $68,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.